The World Cup kicked off this week and so did our clients, with new appointments, important clinical trial updates and major collaborations announced! The Optimum team was proud to support and attend Weatherden’s Symposium on Women’s Health yesterday, which featured a stellar line-up of speakers to explore how smarter clinical development and regulatory strategy can […]
Despite the short Bank Holiday week, it’s as busy as ever. Collaborative expansion is in full swing as Bonito Biosciences and DaltonTx join forces, and ViCentra triples Kaleido consumables production capacity through Phillips Medisize partnership. Hansa Biopharma, Poolbeg Pharma and Synklino have been enjoying progress this week, as Hansa reports positive efficacy and safety results […]
Easter may be over, but momentum across life sciences is building. Anglonordic Life Science Conference is less than two weeks away, alongside a steady stream of clinical progress, partnerships, and industry milestones, it’s all go! Our latest Optimum TV episode features Stephen Hansen of BioCentury and offers fresh insights into market trends and the Q2 […]
Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
28 January 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Read more…
